SCHEMBL2247402

SCHEMBL2247402

CC(C)(OC(=O)[C@H](CCC(N)=O)NC(=O)c1cccc(Oc2ccccc2)c1)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
HDAC8 Q9BY41 1/20 0.44
MRGPRX4 Q96LA9 1/20 0.42
GRN P28799 1/20 0.41
SORT1 Q99523 1/20 0.41
CTSL P07711 2/20 0.41
NPC1 O15118 2/20 0.40
POLB P06746 1/20 0.40
CYP2C9 P11712 1/20 0.40
RAB9A P51151 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
GPR132 Q9UNW8 1/20 0.40
PTPN1 P18031 1/20 0.40
FABP1 P07148 1/20 0.40
HPGDS O60760 1/20 0.40
GPR139 Q6DWJ6 1/20 0.40
GCK P35557 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2247559 0.83 ALDH1A1 (0.58) ALDH1A1LMNASMN1; SMN2HDAC8MRGPRX4
SCHEMBL4623715 0.82 GPR132 (0.53) ALDH1A1LMNASMN1; SMN2HDAC8MRGPRX4
SCHEMBL2244945 0.82 PTPRC (0.47) ALDH1A1LMNASMN1; SMN2CTSLNPC1
SCHEMBL4623549 0.80 ALDH1A1 (0.53) ALDH1A1LMNASMN1; SMN2HDAC8MRGPRX4
SCHEMBL2247555 0.77 HPGDS (0.65) ALDH1A1LMNASMN1; SMN2HDAC8NPC1
SCHEMBL7046034 0.73 CA2 (0.53) ALDH1A1LMNARAB9ACA1CA2
SCHEMBL2249554 0.73 CA2 (0.63) SMN1; SMN2MRGPRX4GRNSORT1CA1
SCHEMBL8248607 0.70 ALDH1A1 (0.72) ALDH1A1LMNASMN1; SMN2HDAC8NPC1
SCHEMBL9632783 0.70 LTA4H (0.47) ALDH1A1CTSLPOLB
SCHEMBL9632782 0.70 LTA4H (0.47) ALDH1A1CTSLPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1902014-A2 GLUTAMATE AGGRECANASE INHIBITORS Wyeth (US) 2008-03-26 EP claimed
US-20070043066-A1 Glutamate aggrecanase inhibitors WYETH (US) 2007-02-22 US claimed
WO-2007008994-A2 GLUTAMATE AGGRECANASE INHIBITORS WYETH (US) 2007-01-18 WO claimed
US-7998965-B2 Glutamate aggrecanase inhibitors WYETH LLC (US) 2011-08-16 US disclosed
US-20100010012-A1 GLUTAMATE AGGRECANASE INHIBITORS WYETH (US) 2010-01-14 US disclosed
US-7553873-B2 Glutamate aggrecanase inhibitors WYETH (US) 2009-06-30 US disclosed
US-20070043066-A1 Glutamate aggrecanase inhibitors WYETH (US) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010012-A1 GLUTAMATE AGGRECANASE INHIBITORS ADAMTS5, ADAMTS1, ADAMTS7 ALDH1A1 991/4885LMNA 4015/4885SMN1; SMN2 2624/4885
US-20070043066-A1 Glutamate aggrecanase inhibitors ADAMTS5, ADAMTS1, ADAMTS7 ALDH1A1 991/4885LMNA 4015/4885SMN1; SMN2 2624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.